- Home
- TRAW vs APLM Comparison
TRAW vs APLM Comparison
Compare TRAW & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRAW
- APLM
- Stock Information
- Founded
- TRAW 1998
- APLM 2016
- Country
- TRAW United States
- APLM United States
- Employees
- TRAW N/A
- APLM N/A
- Industry
- TRAW
- APLM Blank Checks
- Sector
- TRAW
- APLM Finance
- Exchange
- TRAW NYSE
- APLM Nasdaq
- Market Cap
- TRAW 7.8M
- APLM 6.9M
- IPO Year
- TRAW 2013
- APLM N/A
- Fundamental
- Price
- TRAW $1.65
- APLM $6.50
- Analyst Decision
- TRAW
- APLM
- Analyst Count
- TRAW 0
- APLM 0
- Target Price
- TRAW N/A
- APLM N/A
- AVG Volume (30 Days)
- TRAW 3.5M
- APLM 9.8K
- Earning Date
- TRAW 05-15-2025
- APLM 04-03-2025
- Dividend Yield
- TRAW N/A
- APLM N/A
- EPS Growth
- TRAW N/A
- APLM N/A
- EPS
- TRAW N/A
- APLM N/A
- Revenue
- TRAW $227,000.00
- APLM $198,000.00
- Revenue This Year
- TRAW $3.81
- APLM $415.15
- Revenue Next Year
- TRAW $30.43
- APLM N/A
- P/E Ratio
- TRAW N/A
- APLM N/A
- Revenue Growth
- TRAW 0.44
- APLM N/A
- 52 Week Low
- TRAW $0.97
- APLM $4.47
- 52 Week High
- TRAW $19.44
- APLM $35.98
- Technical
- Relative Strength Index (RSI)
- TRAW 54.15
- APLM 53.81
- Support Level
- TRAW $1.30
- APLM $5.96
- Resistance Level
- TRAW $2.58
- APLM $7.39
- Average True Range (ATR)
- TRAW 0.23
- APLM 0.77
- MACD
- TRAW 0.07
- APLM 0.08
- Stochastic Oscillator
- TRAW 34.04
- APLM 54.43
About TRAW TRAWS PHARMA INC
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib.
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.